Cyclacel Pharmaceuticals: Interventions For Cell Cycle Abnormalities In Cancer Hopkins Biotech podcast

Artwork

Science Careers Biology Business Hopkins Biotech

Innhold levert av Hopkins Biotech Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Hopkins Biotech Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Hopkins Biotech Podcast « »
Cyclacel Pharmaceuticals: Interventions for Cell Cycle Abnormalities in Cancer

1+ y ago 38:56

Del

MP3•Episoder hjem

Innhold levert av Hopkins Biotech Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Hopkins Biotech Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Cyclacel Pharmaceuticals is a clinical-stage, biopharmaceutical company, developing innovative cancer medicines based on cell cycle, transcriptional regulation, and mitosis biology with a focus on oncology and hematology indications. Their lead drug candidate, fadraciclib is a dual CDK2/9 inhibitor currently undergoing investigation of dose escalation in a Phase 1/2 trial.

Spiro Rombotis is the founding CEO of Cyclacel. Prior to joining Cyclacel, Spiro served in a number of management positions at public and private biotechs including Centocor, Bristol Myers Squibb, and the Liposome Company. He earned his MBA at Northwestern University’s Kellogg School of Business.

In this episode, we discuss cell cycle dysregulation in cancer, precision targeting of proteins in the drug design process, and unique clinical trial design.

Hosted by Joe Varriale.

… continue reading

84 episoder

#Science #Careers #Biology #Business #Hopkins Biotech

Artwork

Cyclacel Pharmaceuticals: Interventions for Cell Cycle Abnormalities in Cancer

Hopkins Biotech Podcast

27 subscribers

published 1+ y ago

Del

MP3•Episoder hjem

Innhold levert av Hopkins Biotech Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Hopkins Biotech Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Cyclacel Pharmaceuticals is a clinical-stage, biopharmaceutical company, developing innovative cancer medicines based on cell cycle, transcriptional regulation, and mitosis biology with a focus on oncology and hematology indications. Their lead drug candidate, fadraciclib is a dual CDK2/9 inhibitor currently undergoing investigation of dose escalation in a Phase 1/2 trial.

Spiro Rombotis is the founding CEO of Cyclacel. Prior to joining Cyclacel, Spiro served in a number of management positions at public and private biotechs including Centocor, Bristol Myers Squibb, and the Liposome Company. He earned his MBA at Northwestern University’s Kellogg School of Business.

In this episode, we discuss cell cycle dysregulation in cancer, precision targeting of proteins in the drug design process, and unique clinical trial design.

Hosted by Joe Varriale.

… continue reading

84 episoder

#Science #Careers #Biology #Business #Hopkins Biotech

Alle episoder

×

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

Lytt til 500+ tema